ISIN | LU2208649280 |
---|---|
Valor Number | 56107579 |
Bloomberg Global ID | UBSEBQL LX |
Fund Name | UBS (Lux) Equity Fund - Biotech (USD) QL-acc |
Fund Provider |
UBS Asset Management Switzerland AG, Zurich
8098 Zürich, Schweiz E-Mail: ubs-am-wholesale-switzerland@ubs.com Web: www.ubs.com/fonds |
Fund Provider | UBS Asset Management Switzerland AG, Zurich |
Representative in Switzerland |
UBS Fund Management (Switzerland) AG Basel Phone: +41 61 288 49 10 |
Distributor(s) |
UBS Global Asset Management Basel Phone: +41 61 288 20 20 |
Asset Class | Equities |
EFC Category | Equity Global Advanced Markets |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The Fund’s investment objective consists in generating strong capital appreciation with a reasonable level of income, while giving due consideration to capital security and the liquidity of the Fund’s assets. UBS Asset Management categorises this sub-fund as an ESG Integration fund that does not promote particular ESG characteristics or pursues a specific sustainability or impact objective. The sub-fund mainly invests in shares and other equity interests of companies focusing on research, product development, product manufacture and distribution in the biotechnology industry and related sectors. The investments can be made in equities and equity interests of large multinationals or other companies whose products are not yet ready for marketing. Investments are made worldwide without restrictions. For the aforementioned reasons, units in this sub-fund may occasionally exhibit substantial price fluctuations. |
Peculiarities |
Current Price * | 102.97 USD | 30.01.2025 |
---|---|---|
Previous Price * | 101.82 USD | 29.01.2025 |
52 Week High * | 113.07 USD | 29.07.2024 |
52 Week Low * | 91.15 USD | 19.04.2024 |
NAV * | 102.97 USD | 30.01.2025 |
Issue Price * | 102.97 USD | 30.01.2025 |
Redemption Price * | 102.97 USD | 30.01.2025 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 394,878,887 | |
Unit/Share Assets *** | 20,382,151 | |
Trading Information SIX |
YTD Performance | +8.94% |
31.12.2024 - 30.01.2025
31.12.2024 30.01.2025 |
---|---|---|
YTD Performance (in CHF) | +9.18% |
31.12.2024 - 30.01.2025
31.12.2024 30.01.2025 |
1 month | +9.58% |
30.12.2024 - 30.01.2025
30.12.2024 30.01.2025 |
3 months | -0.32% |
30.10.2024 - 30.01.2025
30.10.2024 30.01.2025 |
6 months | -8.62% |
30.07.2024 - 30.01.2025
30.07.2024 30.01.2025 |
1 year | +1.12% |
30.01.2024 - 30.01.2025
30.01.2024 30.01.2025 |
2 years | +2.48% |
30.01.2023 - 30.01.2025
30.01.2023 30.01.2025 |
3 years | +7.92% |
31.01.2022 - 30.01.2025
31.01.2022 30.01.2025 |
5 years | +2.97% |
15.09.2020 - 30.01.2025
15.09.2020 30.01.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Vertex Pharmaceuticals Inc | 9.31% | |
---|---|---|
Alnylam Pharmaceuticals Inc | 6.34% | |
Neurocrine Biosciences Inc | 6.22% | |
AbbVie Inc | 5.01% | |
Gilead Sciences Inc | 4.33% | |
Guardant Health Inc | 4.11% | |
Moderna Inc | 4.02% | |
Amgen Inc | 3.73% | |
Roivant Sciences Ltd Ordinary Shares | 3.58% | |
Denali Therapeutics Inc | 3.24% | |
Last data update | 31.12.2024 |
TER | 0.88% |
---|---|
TER date | 30.11.2023 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 0.66% |
Ongoing Charges *** | 0.89% |
SRRI ***
|
|
SRRI date *** | 31.12.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |